This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maione, T. E. Articles by Sharpe, R. J. Search for Related Content PubMed PubMed Citation Articles by Maione, T. E. Articles by Sharpe, R. J.

Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity

Repligen Corporation, Cambridge, Massachusetts 02139

An analogue of human platelet factor 4 (PF4) lacking affinity for heparin was specifically designed to evaluate the importance of this property in the antitumor effects of recombinant PF4. The purified protein, recombinant PF4-241 (rPF4-241), failed to bind heparin but retained the ability to suppress the growth of tumors in mice. Daily intralesional injections of rPF4-241 significantly inhibited the growth of the B-16 melanoma in syngeneic mice without direct inhibitory effects on B-16 cell growth in vitro. Similar antitumor effects were observed with the human colon carcinoma, HCT-116, grown in nude mice, indicating that the inhibitory activity was neither tumor-type specific nor T-cell dependent. rPF4-241 inhibited endothelial cell proliferation in vitro with dose dependence similar to the native sequence rPF4. Both rPF4 and rPF4-241 inhibited angiogenesis in the chicken chorioallantoic membrane. The analogue, however, was inhibitory at lower concentrations than rPF4 in the chorioallantoic membrane system and its inhibitory effects were not abrogated by the presence of heparin. The present findings support the conclusion that both rPF4 and rPF4-241 inhibit tumor growth by suppression of tumor-induced neovascularization. The finding that this activity is independent of heparin binding may allow the development of PF4-based angiostatic agents with reduced toxicity and improved bioavailability. These results also suggest that PF4 may play a more specific role in modulation of blood vessel development than previously recognized.

Received 10/10/90. Accepted 2/ 1/91.

This article has been cited by other articles:

				B. S. Sachais Platelets may serve up biomarkers Blood, February 1, 2008; 111(3): 974 - 974. [Full Text] [PDF]

				D. Cervi, T.-T. Yip, N. Bhattacharya, V. N. Podust, J. Peterson, A. Abou-Slaybi, G. N. Naumov, E. Bender, N. Almog, J. E. Italiano Jr, et al. Platelet-associated PF-4 as a biomarker of early tumor growth Blood, February 1, 2008; 111(3): 1201 - 1207. [Abstract] [Full Text] [PDF]

				J. D. Altenburg, H. E. Broxmeyer, Q. Jin, S. Cooper, S. Basu, and G. Alkhatib A Naturally Occurring Splice Variant of CXCL12/Stromal Cell-Derived Factor 1 Is a Potent Human Immunodeficiency Virus Type 1 Inhibitor with Weak Chemotaxis and Cell Survival Activities J. Virol., August 1, 2007; 81(15): 8140 - 8148. [Abstract] [Full Text] [PDF]

				S. Struyf, M. D. Burdick, E. Peeters, K. Van den Broeck, C. Dillen, P. Proost, J. Van Damme, and R. M. Strieter Platelet Factor-4 Variant Chemokine CXCL4L1 Inhibits Melanoma and Lung Carcinoma Growth and Metastasis by Preventing Angiogenesis Cancer Res., June 15, 2007; 67(12): 5940 - 5948. [Abstract] [Full Text] [PDF]

				M. E. Daly, A. Makris, M. Reed, and C. E. Lewis Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment? J Natl Cancer Inst, November 19, 2003; 95(22): 1660 - 1673. [Abstract] [Full Text] [PDF]

				C.-Q. Xia and K.-J. Kao Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells Int. Immunol., August 1, 2003; 15(8): 1007 - 1015. [Abstract] [Full Text] [PDF]

				L. Lasagni, M. Francalanci, F. Annunziato, E. Lazzeri, S. Giannini, L. Cosmi, C. Sagrinati, B. Mazzinghi, C. Orlando, E. Maggi, et al. An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 J. Exp. Med., June 2, 2003; 197(11): 1537 - 1549. [Abstract] [Full Text] [PDF]

				J. Middleton, A. M. Patterson, L. Gardner, C. Schmutz, and B. A. Ashton Leukocyte extravasation: chemokine transport and presentation by the endothelium Blood, December 1, 2002; 100(12): 3853 - 3860. [Abstract] [Full Text] [PDF]

				E. Sulpice, M. Bryckaert, J. Lacour, J.-O. Contreres, and G. Tobelem Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway Blood, October 16, 2002; 100(9): 3087 - 3094. [Abstract] [Full Text] [PDF]

				F. Marti, E. Bertran, M. Llucia, E. Villen, M. Peiro, J. Garcia, and F. Rueda Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8 J. Leukoc. Biol., September 1, 2002; 72(3): 590 - 597. [Abstract] [Full Text] [PDF]

				S. Ali, S. J. Fritchley, B. T. Chaffey, and J. A. Kirby Contribution of the putative heparan sulfate-binding motif BBXB of RANTES to transendothelial migration Glycobiology, September 1, 2002; 12(9): 535 - 543. [Abstract] [Full Text] [PDF]

				B. S. Sachais, A. Kuo, T. Nassar, J. Morgan, K. Kariko, K. J. Williams, M. Feldman, M. Aviram, N. Shah, L. Jarett, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface Blood, May 15, 2002; 99(10): 3613 - 3622. [Abstract] [Full Text] [PDF]

				F. Bentzien, I. Struman, J.-F. Martini, J. Martial, and R. Weiner Expression of the Antiangiogenic Factor 16K hPRL in Human HCT116 Colon Cancer Cells Inhibits Tumor Growth in Rag1-/- Mice Cancer Res., October 1, 2001; 61(19): 7356 - 7362. [Abstract] [Full Text] [PDF]

				J. Vakili, L. Standker, M. Detheux, G. Vassart, W.-G. Forssmann, and M. Parmentier Urokinase Plasminogen Activator and Plasmin Efficiently Convert Hemofiltrate CC Chemokine 1 into Its Active [9-74] Processed Variant J. Immunol., September 15, 2001; 167(6): 3406 - 3413. [Abstract] [Full Text] [PDF]

				S. Ali, A. C. V. Palmer, B. Banerjee, S. J. Fritchley, and J. A. Kirby Examination of the Function of RANTES, MIP-1alpha , and MIP-1beta following Interaction with Heparin-like Glycosaminoglycans J. Biol. Chem., April 14, 2000; 275(16): 11721 - 11727. [Abstract] [Full Text] [PDF]

				T. Browder, J. Folkman, and S. Pirie-Shepherd The Hemostatic System as a Regulator of Angiogenesis J. Biol. Chem., January 21, 2000; 275(3): 1521 - 1524. [Full Text] [PDF]

				A. Amara, O. Lorthioir, A. Valenzuela, A. Magerus, M. Thelen, M. Montes, J.-L. Virelizier, M. Delepierre, F. Baleux, H. Lortat-Jacob, et al. Stromal Cell-derived Factor-1alpha Associates with Heparan Sulfates through the First beta -Strand of the Chemokine J. Biol. Chem., August 20, 1999; 274(34): 23916 - 23925. [Abstract] [Full Text] [PDF]

				W. Koopmann, C. Ediriwickrema, and M. S. Krangel Structure and Function of the Glycosaminoglycan Binding Site of Chemokine Macrophage-Inflammatory Protein-1{beta} J. Immunol., August 15, 1999; 163(4): 2120 - 2127. [Abstract] [Full Text] [PDF]

				V. Jouan, X. Canron, M. Alemany, J. P. Caen, G. Quentin, J. Plouet, and A. Bikfalvi Inhibition of In Vitro Angiogenesis by Platelet Factor-4-Derived Peptides and Mechanism of Action Blood, August 1, 1999; 94(3): 984 - 993. [Abstract] [Full Text] [PDF]

				G. Gentilini, N. E. Kirschbaum, J. A. Augustine, R. H. Aster, and G. P. Visentin Inhibition of Human Umbilical Vein Endothelial Cell Proliferation by the CXC Chemokine, Platelet Factor 4 (PF4), Is Associated With Impaired Downregulation of p21Cip1/WAF1 Blood, January 1, 1999; 93(1): 25 - 33. [Abstract] [Full Text] [PDF]

				J. M. Burns, R. C. Gallo, A. L. DeVico, and G. K. Lewis A New Monoclonal Antibody, mAb 4A12, Identifies a Role for the Glycosaminoglycan (GAG) Binding Domain of RANTES in the Antiviral Effect against HIV-1 and Intracellular Ca2+ Signaling J. Exp. Med., November 16, 1998; 188(10): 1917 - 1927. [Abstract] [Full Text] [PDF]

				L. Chakravarty, L. Rogers, T. Quach, S. Breckenridge, and P. E. Kolattukudy Lysine 58 and Histidine 66 at the C-terminal alpha -Helix of Monocyte Chemoattractant Protein-1 Are Essential for Glycosaminoglycan Binding J. Biol. Chem., November 6, 1998; 273(45): 29641 - 29647. [Abstract] [Full Text] [PDF]

				C. Perollet, Z. C. Han, C. Savona, J. P. Caen, and A. Bikfalvi Platelet Factor 4 Modulates Fibroblast Growth Factor 2 (FGF-2) Activity and Inhibits FGF-2 Dimerization Blood, May 1, 1998; 91(9): 3289 - 3299. [Abstract] [Full Text] [PDF]

				L. Lecomte-Raclet, M. Alemany, A. S.-L. Grand, J. Amiral, G. Quentin, A. M. Vissac, J. P. Caen, and Z. C. Han New Insights Into the Negative Regulation of Hematopoiesis by Chemokine Platelet Factor 4 and Related Peptides Blood, April 15, 1998; 91(8): 2772 - 2780. [Abstract] [Full Text] [PDF]

				B. J. Rollins Chemokines Blood, August 1, 1997; 90(3): 909 - 928. [Full Text] [PDF]

				W. Koopmann and M. S. Krangel Identification of a Glycosaminoglycan-binding Site in Chemokine Macrophage Inflammatory Protein-1alpha J. Biol. Chem., April 11, 1997; 272(15): 10103 - 10109. [Abstract] [Full Text] [PDF]

				S. Gengrinovitch, S. M. Greenberg, T. Cohen, H. Gitay-Goren, P. Rockwell, T. E. Maione, B.-Z. Levi, and G. Neufeld Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF[IMAGE] and VEGF[IMAGE] Using Several Concurrent Mechanisms J. Biol. Chem., June 23, 1995; 270(25): 15059 - 15065. [Abstract] [Full Text] [PDF]

				R. M. Lozano, M. Redondo-Horcajo, M. A. Jimenez, L. Zilberberg, P. Cuevas, A. Bikfalvi, M. Rico, and G. Gimenez-Gallego Solution Structure and Interaction with Basic and Acidic Fibroblast Growth Factor of a 3-kDa Human Platelet Factor-4 Fragment with Antiangiogenic Activity J. Biol. Chem., September 14, 2001; 276(38): 35723 - 35734. [Abstract] [Full Text] [PDF]